Freddy Frost1, Paula Dyce2, Dilip Nazareth3, Victoria Malone2, Martin J Walshaw3. 1. Liverpool Adult CF Centre, Liverpool Heart and Chest Hospital, Liverpool L14 3PE, UK. Electronic address: Freddy.Frost@lhch.nhs.uk. 2. Liverpool Adult CF Specialist Diabetes Service, Liverpool Heart and Chest Hospital, L14 3PE, UK. 3. Liverpool Adult CF Centre, Liverpool Heart and Chest Hospital, Liverpool L14 3PE, UK.
Abstract
INTRODUCTION: Continuous glucose monitoring (CGM) allows assessment of day to day glycaemic excursions and detects early glucose handling abnormalities that may not be apparent on oral glucose tolerance testing (OGTT). However, there is little published evidence as to whether these early dysglycaemic changes are amenable to treatment. We present outcomes following CGM guided insulin initiation at our centre. METHODS: Adults without a prior diagnosis of cystic fibrosis related diabetes (CFRD) whom underwent >72 h CGM at our adult CF centre were included in the study. Clinical outcomes including weight and pulmonary function changes over the next 12 months were compared between groups based on CGM results and subsequent management. RESULTS: CGM profiles for 59 patients were analysed. Insulin was commenced in 37 patients who had evidence of hyperglycaemia on CGM. Significant improvements in mean [95% confidence intervals] forced expiratory volume in 1 s (FEV1) (+4.3% predicted [1.06-7.48], p = 0.01) and weight (+1.2 kg [0.32-2.15], p = 0.01) were observed at 3 months in the insulin group. Annual rate of pulmonary function decline was also improved following insulin initiation. CONCLUSION: Insulin treatment targeted towards glycaemic excursions seen on CGM is associated with improvements in lung function and weight with subsequent reduced pulmonary function decline.
INTRODUCTION: Continuous glucose monitoring (CGM) allows assessment of day to day glycaemic excursions and detects early glucose handling abnormalities that may not be apparent on oral glucose tolerance testing (OGTT). However, there is little published evidence as to whether these early dysglycaemic changes are amenable to treatment. We present outcomes following CGM guided insulin initiation at our centre. METHODS: Adults without a prior diagnosis of cystic fibrosis related diabetes (CFRD) whom underwent >72 h CGM at our adult CF centre were included in the study. Clinical outcomes including weight and pulmonary function changes over the next 12 months were compared between groups based on CGM results and subsequent management. RESULTS: CGM profiles for 59 patients were analysed. Insulin was commenced in 37 patients who had evidence of hyperglycaemia on CGM. Significant improvements in mean [95% confidence intervals] forced expiratory volume in 1 s (FEV1) (+4.3% predicted [1.06-7.48], p = 0.01) and weight (+1.2 kg [0.32-2.15], p = 0.01) were observed at 3 months in the insulin group. Annual rate of pulmonary function decline was also improved following insulin initiation. CONCLUSION:Insulin treatment targeted towards glycaemic excursions seen on CGM is associated with improvements in lung function and weight with subsequent reduced pulmonary function decline.
Authors: Jordan S Sherwood; Rabab Z Jafri; Courtney A Balliro; Hui Zheng; Firas H El-Khatib; Edward R Damiano; Steven J Russell; Melissa S Putman Journal: J Cyst Fibros Date: 2019-08-13 Impact factor: 5.482
Authors: Kevin J Scully; Jordan S Sherwood; Kimberly Martin; Melanie Ruazol; Peter Marchetti; Mary Larkin; Hui Zheng; Gregory S Sawicki; Ahmet Uluer; Isabel Neuringer; Lael M Yonker; Leonard Sicilian; Deborah J Wexler; Melissa S Putman Journal: J Clin Endocrinol Metab Date: 2022-03-24 Impact factor: 5.958
Authors: Kevin J Scully; Peter Marchetti; Gregory S Sawicki; Ahmet Uluer; Manuela Cernadas; Rebecca E Cagnina; John C Kennedy; Melissa S Putman Journal: J Cyst Fibros Date: 2021-09-14 Impact factor: 5.482
Authors: Christine L Chan; Laura Pyle; Tim Vigers; Philip S Zeitler; Kristen J Nadeau Journal: J Clin Endocrinol Metab Date: 2022-01-18 Impact factor: 6.134